TP53 and cancer: Our results indicate that p53 may in turn inhibit CDKN2A such that loss of p53 function results in upregulation of CDKN2A. The expression level of another gene, KIF2C (kinesin family member 2C), is also higher in TP53-mutated cancers than in TP53-wildtype cancers in 13 different cancer types: BRCA, LIHC, LUAD, UCEC, KIRC, PAAD, ACC, PRAD, BLCA, SKCM, STAD, SARC and LGG.